AR062775A1 - Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento - Google Patents
Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamentoInfo
- Publication number
- AR062775A1 AR062775A1 ARP070104049A ARP070104049A AR062775A1 AR 062775 A1 AR062775 A1 AR 062775A1 AR P070104049 A ARP070104049 A AR P070104049A AR P070104049 A ARP070104049 A AR P070104049A AR 062775 A1 AR062775 A1 AR 062775A1
- Authority
- AR
- Argentina
- Prior art keywords
- activity
- glp
- polypeptide
- human
- prepare
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composicion farmacéutica capaz de mejorar la actividad de GLP-1 en un ser humano, que comprende al menos un polipéptido que tiene actividad de GLP-1, en donde dicho polipéptido proporciona una concentracion plasmática máxima de dicho polipéptido de al menos aproximadamente 0,6 nM y un valor de área bajo la curva de dicho polipéptido que es al menos aproximadamente 3,5 nM x día durante el período de una semana cuando es administrado a un ser humano. Uso de dicha composicion para preparar un medicamento util para mejorar la actividad GLP-1. Dicho polipéptido que tiene actividad de GLP-1 comprende al menos un agonista de GLP-1. Al menos un agonista de GLP-1 se selecciona entre el grupo de: hormona incretina y/o fragmento, variante y/o conjugado de la misma, y mimético de incretina y/o fragmento, variante y/o conjugado del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82547206P | 2006-09-13 | 2006-09-13 | |
US86839106P | 2006-12-04 | 2006-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062775A1 true AR062775A1 (es) | 2008-12-03 |
Family
ID=39184534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104049A AR062775A1 (es) | 2006-09-13 | 2007-09-12 | Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento |
Country Status (25)
Country | Link |
---|---|
US (3) | US8338369B2 (es) |
EP (1) | EP2073834B1 (es) |
JP (2) | JP5524620B2 (es) |
KR (1) | KR101472601B1 (es) |
CN (1) | CN103705911A (es) |
AR (1) | AR062775A1 (es) |
AU (1) | AU2007296499C1 (es) |
BR (1) | BRPI0716765A8 (es) |
CA (1) | CA2662622C (es) |
CL (1) | CL2007002634A1 (es) |
CR (1) | CR10684A (es) |
EA (1) | EA017159B1 (es) |
ES (1) | ES2442869T3 (es) |
IL (1) | IL197448A (es) |
JO (1) | JO2945B1 (es) |
MA (1) | MA30768B1 (es) |
MX (1) | MX2009002863A (es) |
MY (1) | MY149911A (es) |
NO (1) | NO20091266L (es) |
NZ (1) | NZ575419A (es) |
PE (2) | PE20080840A1 (es) |
SG (2) | SG174770A1 (es) |
TW (1) | TWI430806B (es) |
WO (1) | WO2008033888A2 (es) |
ZA (1) | ZA200901548B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202837B2 (en) | 2005-11-04 | 2012-06-19 | Glaxosmithkline Llc | Methods for administering hypoglycemic agents |
SI2373681T1 (sl) * | 2008-12-10 | 2017-05-31 | Glaxosmithkline Llc Corporation Service Company | Farmacevtski sestavki albiglutida |
JP2013525491A (ja) * | 2010-05-04 | 2013-06-20 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 心血管障害を治療または予防し心血管保護を提供する方法 |
PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
CN103619175B (zh) | 2011-04-12 | 2016-08-17 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
HRP20231060T1 (hr) | 2012-03-22 | 2023-12-22 | Novo Nordisk A/S | Pripravci peptida glp-1 i njihova priprava |
TR201903918T4 (tr) | 2012-03-22 | 2019-04-22 | Novo Nordisk As | Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması. |
CN104487056A (zh) | 2012-06-20 | 2015-04-01 | 诺和诺德A/S(股份有限公司) | 包含肽和递送剂的片剂制剂 |
PL2991671T3 (pl) * | 2013-05-02 | 2019-01-31 | Novo Nordisk As | Doustne dawkowanie związków glp-1 |
PE20151770A1 (es) | 2013-05-28 | 2015-12-11 | Takeda Pharmaceutical | Compuesto peptidico |
CN109477094B (zh) | 2016-05-24 | 2022-04-26 | 武田药品工业株式会社 | 肽化合物 |
EP3746111B1 (en) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
AR125086A1 (es) * | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Composiciones que contienen análogos de incretina y usos de estas |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
DE69739172D1 (de) | 1996-08-08 | 2009-01-29 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
AU764371B2 (en) * | 1998-08-28 | 2003-08-14 | Eli Lilly And Company | Method for administering insulinotropic peptides |
SI1180121T1 (en) * | 1999-05-17 | 2004-04-30 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
CN1501809B (zh) | 2000-12-13 | 2012-10-10 | 伊莱利利公司 | 应用胰高血糖素样促胰岛肽的长期治疗方案 |
AU2002308706A1 (en) * | 2001-06-01 | 2002-12-16 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
KR100593348B1 (ko) * | 2001-08-23 | 2006-06-26 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드-1 유사체 |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
PL377687A1 (pl) | 2001-10-18 | 2006-02-06 | Bristol-Myers Squibb Company | Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą |
WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
PT1463751E (pt) * | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
AU2002364587A1 (en) * | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
TW200306202A (en) | 2002-01-08 | 2003-11-16 | Lilly Co Eli | Extended glucagon-like peptide-1 analogs |
KR100918322B1 (ko) * | 2003-11-12 | 2009-09-22 | 페노믹스 코포레이션 | 헤테로시클릭 보론산 화합물 |
JP4697596B2 (ja) * | 2004-01-13 | 2011-06-08 | 旭硝子株式会社 | 多層積層体 |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
EP1758575A1 (en) * | 2004-06-11 | 2007-03-07 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
US8202837B2 (en) * | 2005-11-04 | 2012-06-19 | Glaxosmithkline Llc | Methods for administering hypoglycemic agents |
WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
-
2007
- 2007-09-11 TW TW096133808A patent/TWI430806B/zh not_active IP Right Cessation
- 2007-09-11 PE PE2007001215A patent/PE20080840A1/es not_active Application Discontinuation
- 2007-09-11 CL CL200702634A patent/CL2007002634A1/es unknown
- 2007-09-11 JO JO2007382A patent/JO2945B1/en active
- 2007-09-11 PE PE2012001061A patent/PE20121528A1/es not_active Application Discontinuation
- 2007-09-12 ES ES07842306.8T patent/ES2442869T3/es active Active
- 2007-09-12 KR KR1020097007414A patent/KR101472601B1/ko active Protection Beyond IP Right Term
- 2007-09-12 BR BRPI0716765A patent/BRPI0716765A8/pt not_active Application Discontinuation
- 2007-09-12 SG SG2011063856A patent/SG174770A1/en unknown
- 2007-09-12 NZ NZ575419A patent/NZ575419A/en not_active IP Right Cessation
- 2007-09-12 MX MX2009002863A patent/MX2009002863A/es active IP Right Grant
- 2007-09-12 AU AU2007296499A patent/AU2007296499C1/en not_active Ceased
- 2007-09-12 US US12/441,152 patent/US8338369B2/en not_active Expired - Fee Related
- 2007-09-12 MY MYPI20090993A patent/MY149911A/en unknown
- 2007-09-12 AR ARP070104049A patent/AR062775A1/es not_active Application Discontinuation
- 2007-09-12 SG SG10201501749WA patent/SG10201501749WA/en unknown
- 2007-09-12 EA EA200970274A patent/EA017159B1/ru not_active IP Right Cessation
- 2007-09-12 EP EP07842306.8A patent/EP2073834B1/en active Active
- 2007-09-12 CA CA2662622A patent/CA2662622C/en not_active Expired - Fee Related
- 2007-09-12 JP JP2009528440A patent/JP5524620B2/ja active Active
- 2007-09-12 CN CN201410014248.3A patent/CN103705911A/zh active Pending
- 2007-09-12 WO PCT/US2007/078226 patent/WO2008033888A2/en active Application Filing
-
2009
- 2009-03-04 ZA ZA2009/01548A patent/ZA200901548B/en unknown
- 2009-03-05 IL IL197448A patent/IL197448A/en active IP Right Grant
- 2009-03-23 CR CR10684A patent/CR10684A/es not_active Application Discontinuation
- 2009-03-26 NO NO20091266A patent/NO20091266L/no not_active Application Discontinuation
- 2009-03-30 MA MA31741A patent/MA30768B1/fr unknown
-
2012
- 2012-06-12 US US13/494,253 patent/US20130005652A1/en not_active Abandoned
-
2013
- 2013-07-19 US US13/946,296 patent/US20140066371A1/en not_active Abandoned
-
2014
- 2014-04-10 JP JP2014081275A patent/JP5753924B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062775A1 (es) | Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento | |
BR9907866A (pt) | Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia | |
EA201070940A1 (ru) | Жидкая лекарственная форма фсг | |
PE20081804A1 (es) | Polipeptidos del receptor de activina variante y usos de los mismos | |
RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
PE20230819A1 (es) | Composiciones y usos de glp-1 | |
AR023806A1 (es) | Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas | |
MX2009011900A (es) | Curacion de herida diabetica. | |
BR112013010829A2 (pt) | composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma | |
AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
UY38067A (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
SE0402345D0 (sv) | A metered medication dose | |
BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
ECSP044979A (es) | Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña | |
PE20020387A1 (es) | Uso de una combinacion de salmeterol y fluticasona | |
CL2002001701A1 (es) | Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno. | |
AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables | |
BRPI0418743A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
JO2492B1 (en) | A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients | |
AR045074A1 (es) | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |